398 related articles for article (PubMed ID: 28863833)
1. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 5 in the link between the innate and acquired immune response.
Takatsu K; Kouro T; Nagai Y
Adv Immunol; 2009; 101():191-236. PubMed ID: 19231596
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
4. IL-5- and eosinophil-mediated inflammation: from discovery to therapy.
Kouro T; Takatsu K
Int Immunol; 2009 Dec; 21(12):1303-9. PubMed ID: 19819937
[TBL] [Abstract][Full Text] [Related]
5. IL-5 and IL-5 receptor in asthma.
Kotsimbos AT; Hamid Q
Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():75-91. PubMed ID: 9698919
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-5 and IL-5 receptor in health and diseases.
Takatsu K
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(8):463-85. PubMed ID: 21986312
[TBL] [Abstract][Full Text] [Related]
7. [Role of interleukin-5 in immune regulation and inflammation].
Takatsu K
Nihon Rinsho; 2004 Oct; 62(10):1941-51. PubMed ID: 15500144
[TBL] [Abstract][Full Text] [Related]
8. IL-5 and eosinophilia.
Takatsu K; Nakajima H
Curr Opin Immunol; 2008 Jun; 20(3):288-94. PubMed ID: 18511250
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
[TBL] [Abstract][Full Text] [Related]
10. Haemopoietic processes in allergic disease: eosinophil/basophil development.
Gauvreau GM; Ellis AK; Denburg JA
Clin Exp Allergy; 2009 Sep; 39(9):1297-306. PubMed ID: 19622087
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
15. Elimination of eosinophils using anti-IL-5 receptor alpha antibodies effectively suppresses IL-33-mediated pulmonary arterial hypertrophy.
Ikutani M; Ogawa S; Yanagibashi T; Nagai T; Okada K; Furuichi Y; Takatsu K
Immunobiology; 2018; 223(6-7):486-492. PubMed ID: 29269115
[TBL] [Abstract][Full Text] [Related]
16. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation.
Asquith KL; Ramshaw HS; Hansbro PM; Beagley KW; Lopez AF; Foster PS
J Immunol; 2008 Jan; 180(2):1199-206. PubMed ID: 18178860
[TBL] [Abstract][Full Text] [Related]
17. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
19. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
20. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
